Drug intelligence / Profile preview

Miyaning

Development stage: Preclinical
Lead developer: Yuebei People's Hospital

Overview

**Miyaning** is an investigational intervention described in the Chinese Clinical Trial Register as the effective or active components of Miyaning for treatment and prevention of kidney stones. The registered study evaluates patients with kidney stones smaller than 10 mm and intends to assess stone treatment, prevention of recurrence, and renal-function protection. Its individual active constituents, formulation, route, dosage form, molecular targets, and pharmacologic mechanism have not been publicly specified. ([chictr.org.cn](https://www.chictr.org.cn/showprojEN.html?proj=275394))

Beyond the preview

Go deeper on Miyaning.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Miyaning.

Explore the full profile